# Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

> **NCT04636008** · PHASE1,PHASE2 · RECRUITING · sponsor: **West China Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Anti-PD-1 Antibody
- Radiotherapy
- Rectal Cancer
- MSI-H
- Mmr Deficiency

## Interventions

- **DRUG:** Sintilimab
- **RADIATION:** Hypofractionated Radiotherapy

## Key facts

- **NCT ID:** NCT04636008
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-08-14
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-08-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04636008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04636008, "Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04636008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*